

## BIOGRAPHY

**Personal Information** Name and Surname: Čedo Miljević Date of Birth: 20 April 1966  
Place of Birth: Zemun, Belgrade, Serbia Mobile: 062/875-9575 E-mail:  
[cedo.miljevic@yahoo.com](mailto:cedo.miljevic@yahoo.com)

**Current Position** Director, Institute of Mental Health, Belgrade

### Education

- 1991 – Graduated from the Faculty of Medicine, University of Belgrade (average grade: 9.07; grade in Neuropsychiatry: 10)
- 1995 – Master’s degree
- 1997 – Board-certified specialist in Psychiatry (with distinction)
- 2001 – PhD in Psychiatry, Faculty of Medicine, University of Belgrade

### Academic Appointments

- 2011 – Clinical Assistant in Psychiatry
- 2018 – Assistant Professor of Psychiatry
- 2024 – Associate Professor of Psychiatry Faculty of Medicine, University of Belgrade

**Teaching Activities** Since 2010, invited lecturer at the Faculty of Chemistry and Faculty of Philosophy, University of Belgrade. Since 2016, lecturer at the Faculty of Pharmacy, University of Belgrade (Pharmacotherapy). Since 2015, delivers lectures in English.

### Professional Career

- 1991–1992 – Medical internship, Clinical Hospital Centre “Bežanijska kosa”
- 1993–2001 – Psychiatrist, Institute for Neuropsychiatric Diseases “Dr Laza Lazarević”
- 2001 – present – Institute of Mental Health, Belgrade
- 2001–2006 – Head of the Department for Psychotic Disorders
- 2006 – present – Head of the Clinical Studies Office
- 2018–2021 – Head of the Department of Specialist Outpatient Consultations for Adults

### Leadership Positions

- 2018–2023 – Vice President of the Serbian Psychiatric Association
- 2023 – present – President of the Serbian Psychiatric Association

**Scientific Work** Author and co-author of more than 40 papers indexed in JCR journals and Medline. Author of numerous chapters in national textbooks. Participant in several scientific projects funded by the Government of the Republic of Serbia, including international projects (PSY-PGx – H2020 and PROMIS programme).

**Research Interests** Psychotic disorders, mood disorders, psychopharmacology, oxidative stress in schizophrenia, and clinical trials.

**Languages** English